title: A controlled study with taltrimide and sodium valproate: valproate effective in partial epilepsy.
abstract: Taltrimide was compared with valproate and placebo in 17 patients with intractable epilepsy being on carbamazepine monotherapy. Taltrimide (400 mg/day), valproate (1000 mg/day) or placebo were added to the treatment for periods of 3 months using a randomized cross-over design. Serum carbamazepine concentrations remained within the therapeutic range throughout the trial. Thirteen patients completed the study. In partial epilepsy of 7 the seizure frequency was reduced by 27% during valproate (p less than 0.05), compared with placebo, while no improvement was found during taltrimide. In 6 with primary generalized epilepsy, the number of seizures was reduced by 49% during taltrimide and by 38% during valproate, but neither effect was significant, compared with placebo. Headache was reported by 3 patients while on taltrimide. One with hypersensitivity history developed petecchiae and nasal bleeding during taltrimide and, therefore, the treatment was stopped. The three other interruptions were independent of taltrimide. Thus, the only statistically significant effect in this study was that of valproate in partial epilepsy.
authors: Department of Neurology, University of Helsinki, Finland.
authors: M
authors: M
authors: Iivanainen
authors: O
authors: O
authors: Waltimo
authors: O
authors: O
authors: Tokola
authors: J
authors: J
authors: Parantainen
authors: M
authors: M
authors: Tamminen
authors: H
authors: H
authors: Allonen
authors: P J
authors: PJ
authors: Neuvonen
mesh_terms: D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000097:blood / Q000627:therapeutic use; D004828:Epilepsies, Partial / Q000097:blood / Q000188:drug therapy*; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010797:Phthalimides / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014635:Valproic Acid / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D010797:Phthalimides; D002220:Carbamazepine; D014635:Valproic Acid; C046932:taltrimide